FDA application made for Ibrutinib in refracto... - CLL Support

CLL Support

23,087 members39,645 posts

FDA application made for Ibrutinib in refractory/relapsed CLL/SLL ONLY

Cllcanada profile image
CllcanadaTop Poster CURE Hero
0 Replies

Janssen Research & Development, LLC announced the submission of a New Drug Application for ibrutinib to the U.S. Food and Drug Administration (FDA) for its use in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and for its use in the treatment of previously treated patients with mantle cell lymphoma (MCL).

The regulatory submission for ibrutinib is supported by data from two pivotal Phase 2 studies, one in relapsed/refractory CLL/SLL (PCYC-1102) and one in relapsed/refractory MCL (PCYC-1104), both of which were published in The New England Journal of Medicine online on June 19, 2013. Ibrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor being jointly developed by Janssen and Pharmacyclics, Inc. for the treatment of B-cell malignancies.

Read more here:

ir.pharmacyclics.com/releas...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Ibrutinib Slow but steady foreward movement.

Slowly things move forwards… New Marketing Authorisation Application Submitted to EMA for...

Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL

Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...

Can anyone confirm if Ibrutinib is now available on prescription in the UK?

I just received an email from a friend to suggest it is available. I’m to start 6 months of BR...

FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018

FDA Approves Duvelisib for CLL and Follicular Lymphoma Published: Monday, Sep 24, 2018 The FDA has...

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...